Kura Oncology, Inc. - Common Stock (KURA)

CUSIP: 50127T109

Q2 2020 13F Holders as of 30 Jun 2020

Type / Class
Equity / Common Stock
Shares outstanding
87,054,674
Total 13F shares
52,442,231
Share change
+12,630,272
Total reported value
$855,540,393
Put/Call ratio
22%
Price per share
$16.30
Number of holders
129
Value change
+$213,208,168
Number of buys
86
Number of sells
44

Quarterly Holders Quick Answers

What is CUSIP 50127T109?
CUSIP 50127T109 identifies KURA - Kura Oncology, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of KURA - Kura Oncology, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
FMR LLC
13F
Company
7.8%
6,814,206
$67,801,000 31 Mar 2020
13F
EcoR1 Capital, LLC
13F
Company
4%
3,511,690
$34,941,000 31 Mar 2020
13F
BlackRock Finance, Inc.
13F
Company
3.4%
2,947,766
$29,329,000 31 Mar 2020
13F
VICTORY CAPITAL MANAGEMENT INC
13F
Company
3%
2,612,819
$25,997,000 31 Mar 2020
13F
BVF INC/IL
13F
Company
2.8%
2,434,696
$24,225,000 31 Mar 2020
13F
VANGUARD GROUP INC
13F
Company
2.5%
2,159,925
$21,491,000 31 Mar 2020
13F
EAGLE ASSET MANAGEMENT INC
13F
Company
2.4%
2,046,984
$20,367,000 31 Mar 2020
13F
Prosight Management, LP
13F
Company
1.7%
1,450,000
$14,428,000 31 Mar 2020
13F
CARILLON TOWER ADVISERS, INC.
13F
Company
1.7%
1,502,217
$13,489,909 31 Mar 2020
13F
STATE STREET CORP
13F
Company
1.2%
1,083,727
$10,783,000 31 Mar 2020
13F
Boxer Capital, LLC
13F
Company
0.97%
844,789
$8,406,000 31 Mar 2020
13F
Cormorant Asset Management, LP
13F
Company
0.92%
800,000
$7,960,000 31 Mar 2020
13F
Ikarian Capital, LLC
13F
Company
0.87%
759,803
$7,560,000 31 Mar 2020
13F
BROWN ADVISORY INC
13F
Company
0.72%
627,667
$6,246,000 31 Mar 2020
13F
CITADEL ADVISORS LLC
13F
Company
0.7%
607,954
$6,049,000 31 Mar 2020
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.67%
580,984
$5,780,000 31 Mar 2020
13F
DIMENSIONAL FUND ADVISORS LP
13F
Company
0.64%
552,909
$5,500,000 31 Mar 2020
13F
ADAGE CAPITAL PARTNERS GP, L.L.C.
13F
Company
0.63%
550,000
$5,473,000 31 Mar 2020
13F
MILLENNIUM MANAGEMENT LLC
13F
Company
0.55%
480,718
$4,783,000 31 Mar 2020
13F
NORTHERN TRUST CORP
13F
Company
0.52%
456,615
$4,543,000 31 Mar 2020
13F
ARCH Venture Management, LLC
13F
Company
0.47%
406,307
$4,043,000 31 Mar 2020
13F
Artal Group S.A.
13F
Company
0.46%
400,000
$3,980,000 31 Mar 2020
13F
Nuveen Asset Management, LLC
13F
Company
0.45%
387,397
$3,854,000 31 Mar 2020
13F
AXA S.A.
13F
Company
0.37%
326,055
$3,244,000 31 Mar 2020
13F
ALETHEA CAPITAL MANAGEMENT, LLC
13F
Company
0.37%
318,992
$3,174,000 31 Mar 2020
13F
DAFNA Capital Management LLC
13F
Company
0.35%
307,541
$3,060,000 31 Mar 2020
13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
13F
Company
0.29%
252,661
$2,514,000 31 Mar 2020
13F
AVIVA PLC
13F
Company
0.29%
248,589
$2,473,000 31 Mar 2020
13F
TWO SIGMA ADVISERS, LP
13F
Company
0.28%
242,000
$2,408,000 31 Mar 2020
13F
WCM INVESTMENT MANAGEMENT, LLC
13F
Company
0.27%
234,560
$2,334,000 31 Mar 2020
13F
ACUTA CAPITAL PARTNERS, LLC
13F
Company
0.23%
198,000
$1,970,000 31 Mar 2020
13F
GREAT POINT PARTNERS LLC
13F
Company
0.21%
179,700
$1,788,000 31 Mar 2020
13F
D. E. Shaw & Co., Inc.
13F
Company
0.2%
173,840
$1,730,000 31 Mar 2020
13F
TWO SIGMA INVESTMENTS, LP
13F
Company
0.19%
165,770
$1,649,000 31 Mar 2020
13F
Erste Asset Management GmbH
13F
Company
0.2%
172,000
$1,613,360 31 Mar 2020
13F
Bank of New York Mellon Corp
13F
Company
0.17%
149,828
$1,491,000 31 Mar 2020
13F
Capital Impact Advisors, LLC
13F
Company
0.16%
140,705
$1,400,000 31 Mar 2020
13F
ALTRINSIC GLOBAL ADVISORS LLC
13F
Company
0.13%
110,000
$1,095,000 31 Mar 2020
13F
KENNEDY CAPITAL MANAGEMENT LLC
13F
Company
0.12%
105,082
$1,046,000 31 Mar 2020
13F
ClariVest Asset Management LLC
13F
Company
0.12%
103,474
$1,031,000 31 Mar 2020
13F
PA Capital LLC
13F
Company
0.12%
100,329
$998,000 31 Mar 2020
13F
GOLDMAN SACHS GROUP INC
13F
Company
0.11%
96,441
$960,000 31 Mar 2020
13F
Foresite Capital Management IV, LLC
13F
Company
0.11%
93,000
$925,000 31 Mar 2020
13F
Squarepoint Ops LLC
13F
Company
0.11%
91,591
$911,000 31 Mar 2020
13F
BOOTHBAY FUND MANAGEMENT, LLC
13F
Company
0.1%
85,849
$854,000 31 Mar 2020
13F
RENAISSANCE TECHNOLOGIES LLC
13F
Company
0.1%
85,271
$848,000 31 Mar 2020
13F
BANK OF AMERICA CORP /DE/
13F
Company
0.09%
82,570
$821,000 31 Mar 2020
13F
ALPS ADVISORS INC
13F
Company
0.09%
82,390
$820,000 31 Mar 2020
13F
ALGERT GLOBAL LLC
13F
Company
0.09%
81,717
$813,000 31 Mar 2020
13F
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM
13F
Company
0.09%
76,454
$761,000 31 Mar 2020
13F

Institutional Holders of Kura Oncology, Inc. - Common Stock (KURA) as of Q2 2020

As of 30 Jun 2020, Kura Oncology, Inc. - Common Stock (KURA) was held by 129 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 52,442,231 shares. The largest 10 holders included FMR LLC, EcoR1 Capital, LLC, BlackRock Inc., BVF INC/IL, VANGUARD GROUP INC, VICTORY CAPITAL MANAGEMENT INC, EAGLE ASSET MANAGEMENT INC, ADAGE CAPITAL PARTNERS GP, L.L.C., STATE STREET CORP, and CARILLON TOWER ADVISERS, INC.. This page lists 129 institutional shareholders reporting positions in this security for the Q2 2020 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q2 2020 vs Q1 2020 Across Filers

Q1 2020 holders
113
Q2 2020 holders
129
Holder diff
16
Investor Q1 2020 Shares Q2 2020 Shares Share Diff Share Chg % Q1 2020 Value $ Q2 2020 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.